QNCX
Quince Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$31.32
+2.52%Next report
Analyst consensus
- Next report date
- Nov 11, 2026
- EPS estimate
- -$1.10
- Revenue estimate
- —
Latest reported
- Last report date
- Aug 14, 2026
- EPS actual
- -$12
- EPS estimate
- -$28
- Revenue actual
- —
- Revenue estimate
- —
Track record
Trailing twelve quarters
- EPS beats (12Q)
- 4
- EPS misses (12Q)
- 4
- EPS in line (12Q)
- 0
- Avg surprise (4Q)
- +9.6%
- Revenue beats (12Q)
- —
Analyst ratings
Sell-side consensus
- Consensus
- Buy
- Price target
- $52
- PT range
- $4.00 – $82
- Analysts
- 3
3 Buy0 Hold0 Sell
Reported results against consensus at the time of each report · Surprise is computed from the estimate on record · Data as of Nov 11, 2026